Other treatment options included PARP inhibitors for BRCA loss, CHEK2 loss, a CDK12 mutation, and an ATM mutation (n = 5), multikinase inhibitors for KDR-, PDGFRA-, and KIT amplifications (n = 4), an activating NTRK mutation (n = 1) and a NRG1 fusion (n = 1), checkpoint inhibitors for a tumor with a high mutational load, excluding the three melanomas, (n = 1), ALK inhibitors for an interstitial ALK deletion (n = 1), MEK inhibitor for a NRAS mutation (n = 1), and ERBB2/3 inhibitors for an ERBB3 amplification (n = 1). This evidence concerns the gene MAP2K7 and neoplasm.